AVA™ Emulation System
AVA™ Emulation System A high-throughput Organ-Chip platform that generates human-relevant data at scale
Receive your quote directly from the manufacturer.
AVA is a self-contained 3-in-1 Organ-Chip platform that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run, delivering in vivo fidelity at scale. AVA is compatible with Chip-Array Organ-Chip consumables, which enable users to create 12 independent Organ-Chip samples per Chip-Array.
Applications:
Cell Models, Cell Culture, 3D Cell Models, Drug Discovery & Development, Organoid Research, Toxicology, cell & gene therapy, cancer, immunology, neuroscience, infectious disease, Organ-on-a-Chip technology.
Media Flow: 15–2,000 µL / h. Different flow rates can be set for top versus bottom microfluidic channels, including no flow if desired.
Capacity: Up to 8 Chip-Arrays for a total of 96 Organ-Chip Emulations per run
Air-Liquid Interface: Yes
Size: 762 x 445 x 559 mm
Weight: 63.5kg
Gas Input: 100% CO2
Relative Humidity: 80-95%
Operating Temperature: 37ºC
Brochures
Organ-on-a-chip technology for drug discovery
This brochure provides an overview of organ‑on‑a‑chip technology, demonstrating how microfluidic culture systems recreate human tissue environments using living cells under physiologically relevant conditions. Featuring platforms such as the Zoë‑CM2® Culture Module and AVA™ Emulation System, the resource shows how controlled flow, stretch, and co‑culture enable more predictive models of human biology, supporting applications in disease modeling, drug discovery, and toxicology. By bridging the gap between in vitro and in vivo studies, these systems help improve translational accuracy and accelerate the development of safer, more effective therapies.
AVA Emulation System
The AVA Emulation System is a high-throughput Organ-Chip platform designed to generate human-relevant biological data at scale. Supporting up to 96 independent Organ-Chip emulations per run, AVA integrates automated imaging, precise flow control, and fully contained environmental conditions to streamline drug discovery and preclinical research. Its benchtop design delivers low operating costs, reduced hands-on time, and enhanced experimental throughput.
Resource details:
- Resource type: Product brochure
- Page count: 2
- Read time: 3 mins
Predicting patient-specific therapeutic responses with organ-on-a-chip technology
This session brings together Dr. Lorenzo Ferri of McGill University and Dr. Donald Ingber of Harvard’s Wyss Institute to showcase a breakthrough in personalized cancer care. Dr. Ferri highlights the challenge of treating esophageal cancer, where traditional chemotherapy often fails and patients endure toxicity without guaranteed benefit. His team now combines patient‑derived organoids with Dr. Ingber’s organ‑on‑a‑chip technology to recreate each patient’s tumor in a dynamic, lifelike environment.
These cancer‑on‑chips accurately predict how an individual will respond to chemotherapy, something organoids alone can’t fully achieve. The platform even reveals how stromal and immune cells shape treatment resistance. Using high‑throughput drug screens, the team identifies existing drugs that can “rescue” chemo‑resistant tumors, converting them into treatment‑responsive ones on the chip.
Organ-on-chip benchtop system for fast and reliable human-relevant data
Looking for a faster, more reliable way to generate human-relevant preclinical data? In this SelectScience interview, Lorna Ewart, CSO at Emulate, presents the AVA™ Emulation System, the first benchtop organ-on-chip platform combining automated microfluidics with high-resolution imaging. Discover how the AVA™ Emulation System enhances lab efficiency, enables streamlined downstream analysis, supports regulatory compliance, and drives the move toward more predictive, ethical, non-animal models in preclinical research.
This video was filmed at SLAS 2026, where Emulate's AVA™ Emulation System won a 2026 SLAS New Product Award.
Human‑relevant drug testing reaches new throughput milestone
How Emulate's 96-chip AVA™ Emulation System is helping pharmaceutical companies transition to human-relevant testing under new FDA and UK regulatory guidelines
Emulate launches AVA emulation system to accelerate drug development with first-of-its-kind high-throughput organ-chip platform
Built-in incubation, automated imaging, and AI-ready data generation deliver in vivo fidelity at scale
